CHINOOK THERAPEUTICS, INC. Income Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Operations and Comprehensive Loss

In millions of USD; shares in millions, except per-share amounts

	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018
Collaboration and license revenue
Collaboration and license revenue
Total collaboration and license revenue

Operating expenses:
Research and development
General and administrative
Loss on impairment of intangible assets
Change in fair value of contingent consideration and contingent value rights liabilities
Amortization of intangible assets
Total operating expenses
Gain on sale of assets to equity method investment
Loss from operations
Interest income, net
Interest expense – related party
Other income (expense), net
Investment and other income (expense):
Investment and other income (expense), net
Change in fair value of redeemable convertible preferred stock tranche liability
Loss before income tax
Loss before income taxes and equity method investment loss
Income tax (expense) benefit
Equity method investment loss
Net loss
Net loss per share attributable to common stockholders, basic
Net loss per share attributable to common stockholders, diluted
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted
Other comprehensive income (loss):
Foreign currency translation adjustments, net of tax of $0
Unrealized loss on marketable securities, net of tax of $0
Total other comprehensive income (loss)
Comprehensive loss

Comments